"Emerging wet AMD therapies including Fovista and abicipar pegol (Allergan/Molecular Partners) will need to be priced competitively to Eylea and Lucentis in order to garner favorable tier placement.

Just a quick not that HROW made another needle moving acquisition, terms not disclosed. BYOOVIZ is a biosimilar for Lucentis, and OPUVIZ is a biosimilar for Eylea. Lucentis and Eylea revenue in 2024 ...

ZURICH (Reuters) - Novartis's bid to move in on Bayer's and Regeneron's eye-drug turf was buoyed on Friday by data showing patients on the Swiss drugmaker's new RTH258 drug showed less disease ...

The results for a proposed aflibercept (Eylea) biosimilar and an accepted ranibizumab (Lucentis) biosimilar were presented at Euretina Congress 2023. Trial results presented at Euretina Congress 2023 ...

Please provide your email address to receive an email when new articles are posted on . FYB203/Ahzantive was comparable to Eylea for the treatment of neovascular age-related macular degeneration. A ...

Eylea is a brand-name biologic prescription medication containing the active ingredient aflibercept. Generic versions of biologic drugs are called biosimilars. Due to the complex manufacturing process ...

Regeneron announced that patients taking an 8 mg high-dose version of its ophthalmology drug Eylea (already approved at a 2 mg dose) were largely able to maintain longer dosing intervals than the ...